je.st
news
Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash
2014-12-08 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & LEXINGTON, Mass. Acquisition Augments Mercks Strong Foundation and Opportunity for Growth in Hospital Acute Care Market KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubists average stock price for the most recent five trading days. Language: English Contact: MerckMedia Contacts:Lainie Keller, 908-406-1459orSteve Cragle, 908-740-1801orInvestor Contacts:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879orCubistMedia Contact:Julie DiCarlo, 781-860-8063orInvestor Contact:Eileen C. McIntyre, 781-860-8100 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: CBST Exchange: NASDAQ read more
Tags: share
cash
acquire
pharmaceuticals
Category:Biotechnology and Pharmaceuticals